Morphine activates neuroinflammation in a manner parallel to endotoxin
暂无分享,去创建一个
Jacob Thomas | Mark R. Hutchinson | L. Watkins | K. Ramos | A. Somogyi | Xiaohui Wang | H. Yin | M. Hutchinson | K. Cheng | Hang Yin | Khara M. Ramos | Linda R. Watkins | Andrew A. Somogyi | Kui Cheng | Xiaohui Wang | Lisa C. Loram | Khara Ramos | Armando J. de Jesus | Anireddy Reddy | Anireddy Reddy | L. Loram | Jacob Thomas | A. J. de Jesus
[1] I. Wilhelm,et al. Expression and regulation of toll-like receptors in cerebral endothelial cells , 2010, Neurochemistry International.
[2] T. Kirikae,et al. Diphosphoryl lipid A derived from the lipopolysaccharide (LPS) of Rhodobacter sphaeroides ATCC 17023 is a potent competitive LPS inhibitor in murine macrophage-like J774.1 cells. , 1994, FEMS immunology and medical microbiology.
[3] S. Maier,et al. Evidence that opioids may have toll-like receptor 4 and MD-2 effects , 2010, Brain, Behavior, and Immunity.
[4] P. Pristovsek,et al. MD‐2 as the target of curcumin in the inhibition of response to LPS , 2007, Journal of leukocyte biology.
[5] L. Watkins,et al. Selection, Preparation, and Evaluation of Small- Molecule Inhibitors of Toll-Like Receptor 4. , 2010, ACS medicinal chemistry letters.
[6] S. Maier,et al. Evidence that intrathecal morphine-3-glucuronide may cause pain enhancement via toll-like receptor 4/MD-2 and interleukin-1β , 2010, Neuroscience.
[7] K. Rice,et al. Stereospecific and nonstereospecific effects of (+)- and (-)-morphine: evidence for a new class of receptors? , 1977, Science.
[8] S. Akira,et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. , 1999, Journal of immunology.
[9] R. Jerala,et al. MD-2 and Der p 2 — a tale of two cousins or distant relatives? , 2005, Journal of endotoxin research.
[10] C. Natanson,et al. Eritoran tetrasodium (E5564) treatment for sepsis: review of preclinical and clinical studies , 2011, Expert opinion on drug metabolism & toxicology.
[11] Hayyoung Lee,et al. The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex , 2009, Nature.
[12] Y. Satow,et al. Crystal Structures of Human MD-2 and Its Complex with Antiendotoxic Lipid IVa , 2007, Science.
[13] R. Dubner,et al. A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia , 1987, Pain.
[14] L. Watkins,et al. Pathological and protective roles of glia in chronic pain , 2009, Nature Reviews Neuroscience.
[15] Kirk W. Johnson,et al. Reduction of opioid withdrawal and potentiation of acute opioid analgesia by systemic AV411 (ibudilast) , 2009, Brain, Behavior, and Immunity.
[16] L. Watkins,et al. A Peptide Antagonist of the TLR4–MD2 Interaction , 2009, Chembiochem : a European journal of chemical biology.
[17] K. Miyake,et al. Inhibition of homodimerization of Toll-like receptor 4 by curcumin. , 2006, Biochemical pharmacology.
[18] L. Watkins,et al. An MD2 Hot‐Spot‐Mimicking Peptide that Suppresses TLR4‐Mediated Inflammatory Response in vitro and in vivo , 2011, Chembiochem : a European journal of chemical biology.
[19] M. Narita,et al. Implication of Activated Astrocytes in the Development of Drug Dependence , 2008, Annals of the New York Academy of Sciences.
[20] Jon Cohen,et al. A randomized, double-blind, placebo-controlled trial of TAK-242 for the treatment of severe sepsis* , 2010, Critical care medicine.
[21] S. Maier,et al. Proinflammatory cytokines oppose opioid-induced acute and chronic analgesia , 2008, Brain, Behavior, and Immunity.
[22] S. Maier,et al. Possible involvement of toll-like receptor 4/myeloid differentiation factor-2 activity of opioid inactive isomers causes spinal proinflammation and related behavioral consequences , 2010, Neuroscience.
[23] Mark R Hutchinson,et al. Application of a novel in silico high-throughput screen to identify selective inhibitors for protein-protein interactions. , 2010, Bioorganic & medicinal chemistry letters.
[24] A. Bytnerowicz,et al. Air Pollution Distribution Patterns in the San Bernardino Mountains of Southern California: a 40-Year Perspective , 2007, TheScientificWorldJournal.
[25] Mark R Hutchinson,et al. The "toll" of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. , 2009, Trends in pharmacological sciences.
[26] Honghong Yao,et al. Morphine enhances Tat-induced activation in murine microglia , 2009, Journal of NeuroVirology.
[27] S. Akira,et al. Pattern Recognition Receptors and Inflammation , 2010, Cell.
[28] L. Watkins,et al. Naloxone-precipitated morphine withdrawal behavior and brain IL-1β expression: Comparison of different mouse strains , 2011, Brain, Behavior, and Immunity.
[29] Kirk W. Johnson,et al. Opioid-Induced Glial Activation: Mechanisms of Activation and Implications for Opioid Analgesia, Dependence, and Reward , 2007, TheScientificWorldJournal.
[30] T. Kirkland,et al. Characterization of monoclonal antibodies to human soluble MD-2 protein. , 2006, Hybridoma.
[31] S. Maier,et al. Minocycline suppresses morphine-induced respiratory depression, suppresses morphine-induced reward, and enhances systemic morphine-induced analgesia , 2008, Brain, Behavior, and Immunity.
[32] H. Yin,et al. Design, synthesis, and evaluation of biotinylated opioid derivatives as novel probes to study opioid pharmacology. , 2008, Bioconjugate chemistry.
[33] S. Maier,et al. Exploring the Neuroimmunopharmacology of Opioids: An Integrative Review of Mechanisms of Central Immune Signaling and Their Implications for Opioid Analgesia , 2011, Pharmacological Reviews.
[34] K. Miyake,et al. MD-2 Enables Toll-Like Receptor 2 (TLR2)-Mediated Responses to Lipopolysaccharide and Enhances TLR2-Mediated Responses to Gram-Positive and Gram-Negative Bacteria and Their Cell Wall Components1 , 2001, The Journal of Immunology.
[35] Makiko Kobayashi,et al. Lipid A antagonist, lipid IVa, is distinct from lipid A in interaction with Toll-like receptor 4 (TLR4)-MD-2 and ligand-induced TLR4 oligomerization. , 2004, International immunology.
[36] P. Pristovsek,et al. Taxanes inhibit human TLR4 signaling by binding to MD‐2 , 2008, FEBS letters.
[37] N. Tsuchimori,et al. TAK-242 (Resatorvid), a Small-Molecule Inhibitor of Toll-Like Receptor (TLR) 4 Signaling, Binds Selectively to TLR4 and Interferes with Interactions between TLR4 and Its Adaptor Molecules , 2011, Molecular Pharmacology.
[38] Sangdun Choi,et al. Similar Structures but Different Roles – An Updated Perspective on TLR Structures , 2011, Front. Physio..